Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s11899-023-00696-6.pdf
Reference29 articles.
1. Takenaka K, Shimoda K, Akashi K. Recent advances in the diagnosis and management of primary myelofibrosis. Korean Journal of Internal Medicine. Korean Assoc Int Med. 2018;33:679–90.
2. • Tremblay D, Mesa R. Novel treatments for myelofibrosis: beyond JAK inhibitors. Int J Hematol. 2022;115(5):645–58. https://doi.org/10.1007/s12185-022-03299-8. Review of the current growing treatment landscape in MF.
3. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145–62.
4. •• Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, et al. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022;18(27):2987–97. First Phase III study assessing combination therapy as first-line treatment for patients with MF without prior JAKi exposure.
5. Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017;10:459–77.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting hematological malignancies with isoxazole derivatives;Drug Discovery Today;2024-08
2. Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis;Journal of Ultrasound;2024-07-26
3. Emerging drug profile: JAK inhibitors;Leukemia & Lymphoma;2024-05-13
4. Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy;Biochemical Pharmacology;2024-05
5. miR‐146a−/− mice model reveals that NF‐κB inhibition reverts inflammation‐driven myelofibrosis‐like phenotype;American Journal of Hematology;2024-04-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3